Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1905 1
1912 1
1915 1
1917 1
1923 1
1927 1
1928 1
1931 1
1932 2
1936 3
1937 3
1938 4
1939 4
1940 1
1942 2
1944 1
1945 6
1946 15
1947 15
1948 21
1949 15
1950 31
1951 23
1952 32
1953 43
1954 34
1955 35
1956 35
1957 50
1958 38
1959 44
1960 26
1961 32
1962 49
1963 85
1964 102
1965 73
1966 66
1967 79
1968 83
1969 94
1970 111
1971 120
1972 117
1973 94
1974 110
1975 84
1976 72
1977 107
1978 75
1979 87
1980 85
1981 75
1982 90
1983 104
1984 88
1985 117
1986 113
1987 104
1988 121
1989 139
1990 105
1991 136
1992 124
1993 143
1994 158
1995 159
1996 173
1997 158
1998 174
1999 151
2000 183
2001 175
2002 219
2003 209
2004 224
2005 255
2006 259
2007 254
2008 295
2009 301
2010 318
2011 354
2012 409
2013 364
2014 391
2015 393
2016 484
2017 477
2018 527
2019 564
2020 656
2021 749
2022 750
2023 722
2024 285

Text availability

Article attribute

Article type

Publication date

Search Results

13,276 results

Results by year

Filters applied: . Clear all
Page 1
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
Wu JQ, Lu MP, Reed AM. Wu JQ, et al. World J Pediatr. 2020 Feb;16(1):31-43. doi: 10.1007/s12519-019-00313-8. Epub 2019 Sep 26. World J Pediatr. 2020. PMID: 31556011 Review.
BACKGROUND: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease characteristic by inflammation of small vessels within the skin, muscle and vital organs. ...RESULTS: Clinical features and myositis-specific antibodies may predict the severity and pr …
BACKGROUND: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease characteristic by inflammation of small vessels wit …
Juvenile Dermatomyositis-Clinical Phenotypes.
Li D, Tansley SL. Li D, et al. Curr Rheumatol Rep. 2019 Dec 11;21(12):74. doi: 10.1007/s11926-019-0871-4. Curr Rheumatol Rep. 2019. PMID: 31828535 Free PMC article. Review.
PURPOSE OF REVIEW: Juvenile dermatomyositis is a heterogeneous disease with variable clinical outcomes. ...RECENT FINDINGS: Large cohort studies have demonstrated that myositis autoantibodies are common in juvenile dermatomyositis and can be fou …
PURPOSE OF REVIEW: Juvenile dermatomyositis is a heterogeneous disease with variable clinical outcomes. ...RECENT FINDINGS: La …
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Rider LG, et al. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S118-57. doi: 10.1002/acr.20532. Arthritis Care Res (Hoboken). 2011. PMID: 22588740 Free PMC article. Review. No abstract available.
Juvenile dermatomyositis. Where are we now?
McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR. McCann LJ, et al. Clin Exp Rheumatol. 2022 Feb;40(2):394-403. doi: 10.55563/clinexprheumatol/56ilob. Epub 2022 Feb 7. Clin Exp Rheumatol. 2022. PMID: 35225221 Free article. Review.
Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common dise …
Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This r …
Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L. He L. Zhongguo Dang Dai Er Ke Za Zhi. 2021 Oct 15;23(10):1064-1068. doi: 10.7499/j.issn.1008-8830.2106011. Zhongguo Dang Dai Er Ke Za Zhi. 2021. PMID: 34719424 Free PMC article. Review. Chinese, English.
Juvenile dermatomyositis (JDM) is an autoimmune disease manifesting as proximal muscle weakness and skin rash and can involve multiple systems and visceral organs. Myositis-specific autoantibodies (MSAs) are highly associated with various complications and pr …
Juvenile dermatomyositis (JDM) is an autoimmune disease manifesting as proximal muscle weakness and skin rash and can involve …
Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Leung AKC, et al. Curr Pediatr Rev. 2021;17(4):273-287. doi: 10.2174/1573396317666210426105045. Curr Pediatr Rev. 2021. PMID: 33902423 Review.
OBJECTIVE: The purpose of this article is to provide readers with an update on the evaluation, diagnosis, and the treatment of juvenile dermatomyositis. METHODS: A PubMed search was performed in Clinical Queries using the key term "juvenile dermatomyositis …
OBJECTIVE: The purpose of this article is to provide readers with an update on the evaluation, diagnosis, and the treatment of juvenile …
Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.
Betteridge Z, McHugh N. Betteridge Z, et al. J Intern Med. 2016 Jul;280(1):8-23. doi: 10.1111/joim.12451. Epub 2015 Nov 25. J Intern Med. 2016. PMID: 26602539 Free article. Review.
In recent years, a number of novel myositis autoantibodies including anti-TIF1, anti-NXP2, anti-MDA5, anti-SAE, anti-HMGCR and anti-cN1A have been identified in both adult and juvenile patients. These autoantibodies correlate with distinct clinical manifestations an …
In recent years, a number of novel myositis autoantibodies including anti-TIF1, anti-NXP2, anti-MDA5, anti-SAE, anti-HMGCR and anti-c …
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Oddis CV, et al. Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754. Arthritis Rheum. 2013. PMID: 23124935 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial in adult and pediatric myositis patients. METHODS: Adults with refractory polymyositis (PM) and adults and children with refractory dermatomyositis (DM) were …
OBJECTIVE: To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial in adult and pediatric myosi …
Dermatomyositis: Clinical features and pathogenesis.
DeWane ME, Waldman R, Lu J. DeWane ME, et al. J Am Acad Dermatol. 2020 Feb;82(2):267-281. doi: 10.1016/j.jaad.2019.06.1309. Epub 2019 Jul 4. J Am Acad Dermatol. 2020. PMID: 31279808 Review.
Dermatomyositis (DM) is an idiopathic inflammatory myopathy that is clinically heterogeneous and that can be difficult to diagnose. Cutaneous manifestations sometimes vary and may or may not parallel myositis and systemic involvement in time course or severity. Rece …
Dermatomyositis (DM) is an idiopathic inflammatory myopathy that is clinically heterogeneous and that can be difficult to diagnose. C …
Dermatomyositis: Diagnosis and treatment.
Waldman R, DeWane ME, Lu J. Waldman R, et al. J Am Acad Dermatol. 2020 Feb;82(2):283-296. doi: 10.1016/j.jaad.2019.05.105. Epub 2019 Jul 4. J Am Acad Dermatol. 2020. PMID: 31279813 Review.
The second article in this continuing medical education series reviews the initial evaluation of patients with suspected dermatomyositis (DM), the relevant work-up for malignancy and interstitial lung disease once a diagnosis of DM is made, and treatment recommendations fo …
The second article in this continuing medical education series reviews the initial evaluation of patients with suspected dermatomyositis …
13,276 results
You have reached the last available page of results. Please see the User Guide for more information.